查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1875878

全球基因检测板市场

Gene Panel
出版日期: | 出版商: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

全球基因检测晶片市场预计到2030年将达到99亿美元

全球基因检测市场规模在2024年估计为34亿美元，预计2030年将达到99亿美元，在分析期间（2024-2030年）内复合年增长率（CAGR）为19.7%。本报告分析的细分市场之一—「癌症风险评估」应用领域，预计将以21.2%的复合年增长率成长，并在分析期结束时达到48亿美元。此外，「先天性疾病诊断」应用领域预计在分析期间内将以19.5%的复合年增长率成长。

美国市场规模估计为9.162亿美元，而中国市场预计将以18.2%的复合年增长率成长。

预计到2024年，美国基因检测市场规模将达到9.162亿美元。作为世界第二大经济体，中国预计到2030年市场规模将达到15亿美元，在2024年至2030年的分析期间内，复合年增长率（CAGR）将达到18.2%。其他值得关注的区域市场包括日本和加拿大，预计在分析期内，这两个市场的复合年增长率将分别达到18.1%和16.7%。在欧洲，德国的复合年增长率预计将达到约13.9%。

全球基因检测市场—关键趋势与驱动因素概述

为什么基因组检测在现代基因组医学中至关重要？

基因检测已成为现代基因组医学中不可或缺的工具，彻底改变了遗传性疾病、癌症和先天性疾病的诊断和治疗方式。那么，基因检测为何如此重要？基因检测是一种定序定序，专注于与特定疾病或病症相关的特定基因。与分析整个基因组的全基因测序不同，基因检测聚焦于已知与特定疾病相关的基因，从而实现更具针对性、更经济高效且更快速的分析。这种精准性对于医疗服务提供者至关重要，能够帮助他们更快、更准确地做出诊断，并制定个人化的治疗方案。

例如，在肿瘤学领域，基因检测可用于识别癌症相关基因的突变，并根据肿瘤的基因组成製定个人化治疗方法。 BRCA1 和 BRCA2 等基因的突变显示乳癌或卵巢癌的风险更高，并可指南预防措施或特定治疗。在其他领域，例如心臟病学和神经病学，基因检测有助于识别遗传性心臟疾病、神经退化性疾病或儿童发育迟缓的遗传病因。透过聚焦于疾病特异性基因，基因检测提供了一种高度标靶的方法来了解遗传因素，从而实现更有效、更个人化的医疗解决方案。

科技进步如何提升基因检测组合的效能？

技术进步显着提升了基因panel的性能、准确性和可用性，进一步增强了其在临床和研究领域的价值。其中最具影响力的进步之一是次世代定序（NGS）技术的发展，它彻底革新了基因体学领域。 NGS能够在一次检测中并行定序多个基因，与传统定序方法相比，能够以更低的成本和更短的时间提供快速、全面的遗传数据。这使得基因panel更加经济实惠且易于获取，从而得以在临床诊断，特别是精准医疗领域得到广泛应用。

另一项关键创新是用于解读基因组数据的生物资讯学工具的进步。鑑于新一代定序（NGS）产生的数据量庞大，先进的生物资讯演算法对于识别致病变异、排除良性变异以及评估基因观察的临床意义至关重要。这些工具能够帮助临床医生根据基因组检测结果做出更明智的决策，进而提高诊断准确性和治疗效果。此外，云端基础的数据储存和分析平台使医疗服务提供者能够即时存取和分析基因数据，从而简化诊断实验室的工作流程并提高基因检测的效率。

此外，基因检测技术的进步使得基因检测更加个人化和全面。现在可以根据特定患者的症状、家族病史和疾病风险，设计客製化的基因检测方案，并专注于相关的基因组。这些方案还可以扩展和完善，纳入新的遗传标记和最新的疾病相关基因研究成果。这种灵活性在罕见疾病研究中尤其重要，因为它可以设计针对罕见基因变异的客製化基因检测方案，这些罕见基因变异可能与患者的病情有关。这些技术进步提高了基因检测的准确性、速度和灵活性，使基因检测更加有效，并广泛应用于多个医学领域。

为什么基因检测对个人化医疗和早期检测至关重要？

基因检测在个人化医疗中发挥着至关重要的作用，它能提供精准的基因讯息，从而为每位患者量身定制治疗方案。基因检测的关键优势之一在于其能够识别与疾病相关的特定突变或变异，使医疗专业人员能够做出更明智的患者照护决策。例如，在癌症治疗中，基因检测可以检测驱动肿瘤生长的基因突变，例如肺癌中的EGFR突变和结直肠癌中的KRAS突变。掌握这些资讯后，肿瘤科医师可以针对特定的基因谱系製定更有效的标靶治疗，从而改善患者预后并降低副作用风险。

基因检测对于早期发现和预防遗传性疾病至关重要。对于有遗传性疾病或癌症家族病史的个体，基因检测可以辨识BRCA1和BRCA2等基因的突变。这些突变与乳癌、卵巢和其他癌症的风险增加有关。早期发现这些突变有助于采取积极措施，例如强化后续观察、改变生活方式和预防性手术，从而降低患病风险。同样，用于产前和孕前检测的基因检测可以识别囊肿纤维化和戴-萨克斯病等遗传性疾病的携带者状态，使家庭能够做出知情的生育决定。

除了癌症之外，基因检测在心臟病学领域也被广泛应用，用于检测与遗传性心臟病（例如肥厚型心肌病和致心律失常性右室心肌病变）相关的基因突变。早期识别这些遗传标记有助于更密切的监测、早期疗育和个人化治疗，从而预防诸如心臟麻痹等併发症。由于基因检测能够在症状出现之前或疾病早期阶段检测到基因突变，因此它们是疾病预防、早期疗育和个体化治疗策略中不可或缺的工具，能够确保患者根据其基因组成获得最有效的治疗。

哪些因素正在推动基因检测市场的成长？

基因检测市场正经历快速成长，这主要得益于几个关键因素，包括基因检测技术的进步、个人化医疗需求的不断增长以及遗传疾病盛行率的上升。首先，次世代定序（NGS）技术的发展彻底改变了基因检测市场。 NGS显着降低了多基因定序的成本和时间，使基因检测更加经济实惠，也更容易被更广泛的医疗服务提供者和患者所接受。这促使基因检测在临床实务上已广泛应用，如今已广泛应用于诊断、肿瘤学、心臟病学、罕见疾病研究等领域。

其次，对个人化医疗日益增长的需求是基因检测市场的主要驱动力。随着医疗保健朝着更个人化的治疗方式发展，基于患者基因谱客製化治疗方法的能力变得愈发重要。基因检测能够提供做出明智治疗决策所需的特定基因讯息，尤其是在癌症治疗中，可以根据患者的基因突变选择标靶治疗。这种对精准医疗的需求正在推动基因检测的研究和临床应用，使治疗更加个人化和有效。

第三，遗传性疾病和癌症的日益普遍推动了基因检测需求的成长。癌症、心血管疾病、神经退化性疾病和其他疾病发生率的上升，促使人们更需要早期检测和精准诊断。基因检测为识别与这些疾病相关的遗传风险因素和突变提供了强有力的工具，从而实现早期疗育并改善患者预后。此外，基因检测也广​​泛应用于产前检测，能够检测胎儿的基因异常，从而实现早期诊断并为潜在的健康问题做好准备。

此外，监管核准和日益增强的医学意识正在推动市场成长。随着各国政府和医疗机构越来越认识到基因检测的价值，用于临床的基因检测组合的核准也不断增加。这促进了基因检测的普及，并扩大了其在主流医疗保健领域的应用范围。大众对基因检测及其益处的认识不断提高，也推动了市场需求，因为患者越来越希望了解自身的遗传健康风险和治疗方案。

最后，面向消费者的基因检测（DTC）的兴起也推动了基因检测组合市场的扩张。提供祖源、健康风险和携带者状态等基因检测服务的公司正越来越多地将基因检测组合纳入其服务范围，使基因检测能够更广泛地惠及大众。随着越来越多的人能够获得个人化的基因资讯来指南其医疗决策，这一趋势正在进一步扩大市场。

总之，基因检测市场成长的驱动因素包括：次世代定序技术的进步、个人化医疗需求的不断增长、遗传疾病盛行率的上升、监管支持以及面向消费者的基因检测的普及。随着基因检测日益融入常规医疗保健，基因检测将在推动诊断进步、个人化治疗和疾病预防方面继续发挥关键作用，其应用范围涵盖广泛的医疗保健领域。

部分：

产品/服务（检测套组、检测服务），用途（癌症风险评估、先天性疾病诊断、药物基因学、其他用途），最终用户（医院/诊断实验室、製药/生物技术公司、研究/学术机构）

受访公司范例

  • Agilent Technologies, Inc.
  • ArcherDX, Inc.
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche AG
  • GATC Biotech AG
  • GENEWIZ
  • Illumina, Inc.
  • Integrated DNA Technologies（IDT）, Inc.
  • Personalis, Inc.
  • QIAGEN GmbH
  • Thermo Fisher Scientific, Inc.

人工智慧集成

我们正在利用检验的专家内容和人工智慧工具，革新市场和竞争情报分析。

Market Glass, Inc. 并没有查询LLM 或产业专用的SLM 的典型方法，而是建立了一个由世界各地领域专家精心策划的内容库，其中包括视频转录、博客、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

在最新发布的报告中，Market Glass, Inc. 将关税对地理市场的影响纳入考量，并根据公司总部所在国、製造地以及进出口（成品和OEM产品）情况，预测企业竞争格局的变化。这种复杂多变的市场现实将对竞争对手产生多方面的影响，包括销货成本增加、盈利下降和供应链重组，同时也会影响微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章 市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他欧洲
  • 亚太地区
  • 世界其他地区

第四章 竞赛

简介目录
Product Code: MCP12156

Global Gene Panel Market to Reach US$9.9 Billion by 2030

The global market for Gene Panel estimated at US$3.4 Billion in the year 2024, is expected to reach US$9.9 Billion by 2030, growing at a CAGR of 19.7% over the analysis period 2024-2030. Cancer Risk Assessment Application, one of the segments analyzed in the report, is expected to record a 21.2% CAGR and reach US$4.8 Billion by the end of the analysis period. Growth in the Diagnosis of Congenital Diseases Application segment is estimated at 19.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$916.2 Million While China is Forecast to Grow at 18.2% CAGR

The Gene Panel market in the U.S. is estimated at US$916.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.5 Billion by the year 2030 trailing a CAGR of 18.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 18.1% and 16.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.9% CAGR.

Global Gene Panel Market - Key Trends and Drivers Summarized

Why Are Gene Panels Essential in Modern Genomic Medicine?

Gene panels have become an indispensable tool in modern genomic medicine, revolutionizing how genetic disorders, cancers, and inherited diseases are diagnosed and treated. But why are gene panels so crucial today? Gene panels are targeted sequencing tests that focus on a specific set of genes related to a particular disease or medical condition. Unlike whole-genome sequencing, which analyzes the entire genome, gene panels allow for a more focused, cost-effective, and quicker analysis by honing in on genes known to be associated with certain diseases. This precision is essential for healthcare providers in making faster, more accurate diagnoses and guiding personalized treatment plans.

In oncology, for instance, gene panels are used to identify mutations in cancer-related genes, allowing oncologists to tailor treatments based on the genetic makeup of a patient's tumor. For example, mutations in genes like BRCA1 and BRCA2 can indicate a higher risk for breast or ovarian cancer, guiding preventive measures or specific therapies. In other fields, such as cardiology and neurology, gene panels help identify the genetic causes of inherited heart diseases, neurodegenerative disorders, or developmental delays in children. By focusing on disease-specific genes, gene panels offer a highly targeted approach to understanding genetic factors, allowing for more effective and personalized healthcare solutions.

How Are Technological Advancements Enhancing the Performance of Gene Panels?

Technological advancements are significantly enhancing the performance, accuracy, and accessibility of gene panels, making them even more valuable in both clinical and research settings. One of the most impactful advancements is the development of next-generation sequencing (NGS) technology, which has revolutionized the field of genomics. NGS allows for the parallel sequencing of multiple genes in a single test, providing fast, comprehensive genetic data at a fraction of the cost and time compared to older sequencing methods. This has made gene panels more affordable and accessible, enabling widespread use in clinical diagnostics, especially in personalized medicine.

Another important innovation is the refinement of bioinformatics tools used to interpret gene panel data. With the vast amount of data generated by NGS, advanced bioinformatics algorithms are critical for identifying pathogenic variants, filtering out benign mutations, and assessing the clinical significance of genetic findings. These tools help clinicians make more informed decisions based on the results of gene panels, leading to improved diagnostic accuracy and treatment outcomes. Additionally, cloud-based data storage and analysis platforms now allow healthcare providers to access and analyze genetic data in real time, streamlining the workflow for diagnostic labs and making genetic testing more efficient.

Further, advancements in gene panel design are enabling more customizable and comprehensive testing. Custom panels can now be tailored to focus on specific sets of genes relevant to a particular patient’s symptoms, family history, or disease risks. These panels can be expanded or refined to include emerging genetic markers or the latest discoveries in disease-related genes. This flexibility is particularly useful in rare disease research, where custom gene panels can be designed to target less common genetic mutations that may be relevant to a patient’s condition. By improving the precision, speed, and flexibility of gene panels, these technological advancements are making genetic testing more effective and widely applicable across multiple medical fields.

Why Are Gene Panels Critical for Personalized Medicine and Early Detection?

Gene panels play a pivotal role in personalized medicine, providing the precise genetic information needed to tailor treatments to individual patients. One of the key advantages of gene panels is their ability to identify specific mutations or variants associated with diseases, allowing healthcare providers to make more informed decisions about patient care. In cancer treatment, for instance, gene panels can detect mutations in genes that drive tumor growth, such as EGFR in lung cancer or KRAS in colorectal cancer. With this information, oncologists can prescribe targeted therapies that are more likely to be effective for a particular genetic profile, improving patient outcomes and reducing the risk of side effects.

Gene panels are also essential for early detection and prevention of hereditary diseases. In individuals with a family history of genetic disorders or cancer, gene panels can identify mutations in genes like BRCA1 or BRCA2, which are linked to an increased risk of breast, ovarian, and other cancers. Early detection of such mutations allows for proactive measures, such as enhanced surveillance, lifestyle changes, or preventive surgeries, to reduce the risk of developing the disease. Similarly, gene panels used in prenatal and preconception testing can identify carrier status for inherited conditions like cystic fibrosis or Tay-Sachs disease, enabling families to make informed reproductive decisions.

In addition to cancer, gene panels are widely used in cardiology to detect mutations linked to inherited heart conditions, such as hypertrophic cardiomyopathy or arrhythmogenic right ventricular dysplasia. Early identification of these genetic markers allows for closer monitoring, early intervention, and personalized treatments to prevent complications like sudden cardiac arrest. The ability of gene panels to detect genetic mutations before symptoms appear or in the early stages of disease makes them invaluable tools for disease prevention, early intervention, and personalized treatment strategies, ensuring that patients receive the most effective care based on their genetic makeup.

What Factors Are Driving the Growth of the Gene Panel Market?

The gene panel market is experiencing rapid growth, driven by several key factors, including advancements in genetic testing technologies, the increasing demand for personalized medicine, and the rising prevalence of genetic and hereditary diseases. First, the development of next-generation sequencing (NGS) technology has been a game-changer for the gene panel market. NGS has significantly reduced the cost and time required to sequence multiple genes, making gene panels more affordable and accessible to a wider range of healthcare providers and patients. This has expanded the use of gene panels in clinical settings, where they are now commonly used in diagnostics, oncology, cardiology, and rare disease research.

Second, the growing demand for personalized medicine is a major driver of the gene panel market. As healthcare shifts toward more individualized treatment approaches, the ability to tailor therapies based on a patient’s genetic profile is becoming increasingly important. Gene panels provide the specific genetic information needed to make informed treatment decisions, particularly in cancer, where targeted therapies can be matched to a patient’s genetic mutations. This demand for precision medicine is driving the adoption of gene panels in both research and clinical settings, as they allow for more personalized and effective care.

Third, the increasing prevalence of genetic disorders and cancers is contributing to the rising demand for gene panels. With the growing incidence of diseases like cancer, cardiovascular disorders, and neurodegenerative diseases, there is a heightened need for early detection and accurate diagnosis. Gene panels offer a powerful tool for identifying genetic risk factors and mutations associated with these diseases, enabling early intervention and improved patient outcomes. Additionally, gene panels are widely used in prenatal testing, where they can detect genetic abnormalities in fetuses, allowing for early diagnosis and preparation for potential health issues.

Moreover, regulatory approvals and growing healthcare awareness are accelerating market growth. As governments and healthcare organizations increasingly recognize the value of genetic testing, more gene panels are receiving regulatory approval for clinical use. This is making genetic testing more widely available and expanding its use in mainstream healthcare. Increased public awareness about genetic testing and its benefits is also driving demand, as patients seek more information about their genetic health risks and treatment options.

Lastly, the rise of direct-to-consumer (DTC) genetic testing services is contributing to the expansion of the gene panel market. Companies offering consumer-accessible genetic tests for ancestry, health risks, and carrier status are increasingly incorporating gene panels into their offerings, making genetic testing more widely available to the general public. This trend is further expanding the market as more individuals gain access to personalized genetic information that can guide their healthcare decisions.

In conclusion, the growth of the gene panel market is being driven by advancements in next-generation sequencing, the increasing demand for personalized medicine, the rising prevalence of genetic diseases, regulatory support, and the expansion of direct-to-consumer genetic testing. As genetic testing becomes more integrated into everyday healthcare, gene panels will continue to play a crucial role in advancing diagnostics, personalized treatment, and disease prevention across a wide range of medical fields.

SCOPE OF STUDY:

The report analyzes the Gene Panel market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product & Service (Test Kits, Testing Services); Application (Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics, Other Applications); End-Use (Hospital & Diagnostic Laboratories, Pharma & Biotech Companies, Research & Academic Institutes)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 47 Featured) -

  • Agilent Technologies, Inc.
  • ArcherDX, Inc.
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche AG
  • GATC Biotech AG
  • GENEWIZ
  • Illumina, Inc.
  • Integrated DNA Technologies (IDT), Inc.
  • Personalis, Inc.
  • QIAGEN GmbH
  • Thermo Fisher Scientific, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • Global Economic Update
    • Gene Panel - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Surge in Genetic Testing and Personalized Medicine Boosts Demand for Gene Panels
    • Advances in Next-Generation Sequencing (NGS) Technologies Enhance Gene Panel Accuracy
    • Growth in Oncology Research Drives Adoption of Cancer-Specific Gene Panels
    • Role of Gene Panels in Rare Disease Diagnosis and Treatment Strategies
    • Market Opportunities in Prenatal and Newborn Screening Applications
    • Consumer Demand for Direct-to-Consumer Genetic Testing Kits
    • Role of Gene Panels in Pharmacogenomics and Drug Response Profiling
    • Impact of Artificial Intelligence and Machine Learning on Gene Panel Development
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Cancer Risk Assessment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 2: World 6-Year Perspective for Cancer Risk Assessment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 3: World Recent Past, Current & Future Analysis for Diagnosis of Congenital Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 4: World 6-Year Perspective for Diagnosis of Congenital Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Pharmacogenetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World 6-Year Perspective for Pharmacogenetics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 8: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 9: World Recent Past, Current & Future Analysis for Test Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 10: World 6-Year Perspective for Test Kits by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Testing Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World 6-Year Perspective for Testing Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Hospital & Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 14: World 6-Year Perspective for Hospital & Diagnostic Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 15: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 16: World 6-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Research & Academic Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World 6-Year Perspective for Research & Academic Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 19: World Gene Panel Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Gene Panel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Gene Panel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Gene Panel Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 22: USA Recent Past, Current & Future Analysis for Gene Panel by Application - Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 23: USA 6-Year Perspective for Gene Panel by Application - Percentage Breakdown of Value Sales for Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics and Other Applications for the Years 2025 & 2030
    • TABLE 24: USA Recent Past, Current & Future Analysis for Gene Panel by Product & Service - Test Kits and Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 25: USA 6-Year Perspective for Gene Panel by Product & Service - Percentage Breakdown of Value Sales for Test Kits and Testing Services for the Years 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Gene Panel by End-Use - Hospital & Diagnostic Laboratories, Pharma & Biotech Companies and Research & Academic Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA 6-Year Perspective for Gene Panel by End-Use - Percentage Breakdown of Value Sales for Hospital & Diagnostic Laboratories, Pharma & Biotech Companies and Research & Academic Institutes for the Years 2025 & 2030
  • CANADA
    • TABLE 28: Canada Recent Past, Current & Future Analysis for Gene Panel by Application - Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 29: Canada 6-Year Perspective for Gene Panel by Application - Percentage Breakdown of Value Sales for Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics and Other Applications for the Years 2025 & 2030
    • TABLE 30: Canada Recent Past, Current & Future Analysis for Gene Panel by Product & Service - Test Kits and Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Canada 6-Year Perspective for Gene Panel by Product & Service - Percentage Breakdown of Value Sales for Test Kits and Testing Services for the Years 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Gene Panel by End-Use - Hospital & Diagnostic Laboratories, Pharma & Biotech Companies and Research & Academic Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada 6-Year Perspective for Gene Panel by End-Use - Percentage Breakdown of Value Sales for Hospital & Diagnostic Laboratories, Pharma & Biotech Companies and Research & Academic Institutes for the Years 2025 & 2030
  • JAPAN
    • Gene Panel Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 34: Japan Recent Past, Current & Future Analysis for Gene Panel by Application - Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Japan 6-Year Perspective for Gene Panel by Application - Percentage Breakdown of Value Sales for Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics and Other Applications for the Years 2025 & 2030
    • TABLE 36: Japan Recent Past, Current & Future Analysis for Gene Panel by Product & Service - Test Kits and Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Japan 6-Year Perspective for Gene Panel by Product & Service - Percentage Breakdown of Value Sales for Test Kits and Testing Services for the Years 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Gene Panel by End-Use - Hospital & Diagnostic Laboratories, Pharma & Biotech Companies and Research & Academic Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan 6-Year Perspective for Gene Panel by End-Use - Percentage Breakdown of Value Sales for Hospital & Diagnostic Laboratories, Pharma & Biotech Companies and Research & Academic Institutes for the Years 2025 & 2030
  • CHINA
    • Gene Panel Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 40: China Recent Past, Current & Future Analysis for Gene Panel by Application - Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: China 6-Year Perspective for Gene Panel by Application - Percentage Breakdown of Value Sales for Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics and Other Applications for the Years 2025 & 2030
    • TABLE 42: China Recent Past, Current & Future Analysis for Gene Panel by Product & Service - Test Kits and Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: China 6-Year Perspective for Gene Panel by Product & Service - Percentage Breakdown of Value Sales for Test Kits and Testing Services for the Years 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Gene Panel by End-Use - Hospital & Diagnostic Laboratories, Pharma & Biotech Companies and Research & Academic Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China 6-Year Perspective for Gene Panel by End-Use - Percentage Breakdown of Value Sales for Hospital & Diagnostic Laboratories, Pharma & Biotech Companies and Research & Academic Institutes for the Years 2025 & 2030
  • EUROPE
    • Gene Panel Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 46: Europe Recent Past, Current & Future Analysis for Gene Panel by Application - Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Europe 6-Year Perspective for Gene Panel by Application - Percentage Breakdown of Value Sales for Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics and Other Applications for the Years 2025 & 2030
    • TABLE 48: Europe Recent Past, Current & Future Analysis for Gene Panel by Product & Service - Test Kits and Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Europe 6-Year Perspective for Gene Panel by Product & Service - Percentage Breakdown of Value Sales for Test Kits and Testing Services for the Years 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Gene Panel by End-Use - Hospital & Diagnostic Laboratories, Pharma & Biotech Companies and Research & Academic Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe 6-Year Perspective for Gene Panel by End-Use - Percentage Breakdown of Value Sales for Hospital & Diagnostic Laboratories, Pharma & Biotech Companies and Research & Academic Institutes for the Years 2025 & 2030
    • TABLE 52: Europe Recent Past, Current & Future Analysis for Gene Panel by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 53: Europe 6-Year Perspective for Gene Panel by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
  • FRANCE
    • Gene Panel Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 54: France Recent Past, Current & Future Analysis for Gene Panel by Application - Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: France 6-Year Perspective for Gene Panel by Application - Percentage Breakdown of Value Sales for Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics and Other Applications for the Years 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Gene Panel by Product & Service - Test Kits and Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France 6-Year Perspective for Gene Panel by Product & Service - Percentage Breakdown of Value Sales for Test Kits and Testing Services for the Years 2025 & 2030
    • TABLE 58: France Recent Past, Current & Future Analysis for Gene Panel by End-Use - Hospital & Diagnostic Laboratories, Pharma & Biotech Companies and Research & Academic Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: France 6-Year Perspective for Gene Panel by End-Use - Percentage Breakdown of Value Sales for Hospital & Diagnostic Laboratories, Pharma & Biotech Companies and Research & Academic Institutes for the Years 2025 & 2030
  • GERMANY
    • Gene Panel Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 60: Germany Recent Past, Current & Future Analysis for Gene Panel by Application - Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Germany 6-Year Perspective for Gene Panel by Application - Percentage Breakdown of Value Sales for Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics and Other Applications for the Years 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Gene Panel by Product & Service - Test Kits and Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany 6-Year Perspective for Gene Panel by Product & Service - Percentage Breakdown of Value Sales for Test Kits and Testing Services for the Years 2025 & 2030
    • TABLE 64: Germany Recent Past, Current & Future Analysis for Gene Panel by End-Use - Hospital & Diagnostic Laboratories, Pharma & Biotech Companies and Research & Academic Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Germany 6-Year Perspective for Gene Panel by End-Use - Percentage Breakdown of Value Sales for Hospital & Diagnostic Laboratories, Pharma & Biotech Companies and Research & Academic Institutes for the Years 2025 & 2030
  • ITALY
    • TABLE 66: Italy Recent Past, Current & Future Analysis for Gene Panel by Application - Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Italy 6-Year Perspective for Gene Panel by Application - Percentage Breakdown of Value Sales for Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics and Other Applications for the Years 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Gene Panel by Product & Service - Test Kits and Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy 6-Year Perspective for Gene Panel by Product & Service - Percentage Breakdown of Value Sales for Test Kits and Testing Services for the Years 2025 & 2030
    • TABLE 70: Italy Recent Past, Current & Future Analysis for Gene Panel by End-Use - Hospital & Diagnostic Laboratories, Pharma & Biotech Companies and Research & Academic Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Italy 6-Year Perspective for Gene Panel by End-Use - Percentage Breakdown of Value Sales for Hospital & Diagnostic Laboratories, Pharma & Biotech Companies and Research & Academic Institutes for the Years 2025 & 2030
  • UNITED KINGDOM
    • Gene Panel Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 72: UK Recent Past, Current & Future Analysis for Gene Panel by Application - Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: UK 6-Year Perspective for Gene Panel by Application - Percentage Breakdown of Value Sales for Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics and Other Applications for the Years 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Gene Panel by Product & Service - Test Kits and Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK 6-Year Perspective for Gene Panel by Product & Service - Percentage Breakdown of Value Sales for Test Kits and Testing Services for the Years 2025 & 2030
    • TABLE 76: UK Recent Past, Current & Future Analysis for Gene Panel by End-Use - Hospital & Diagnostic Laboratories, Pharma & Biotech Companies and Research & Academic Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: UK 6-Year Perspective for Gene Panel by End-Use - Percentage Breakdown of Value Sales for Hospital & Diagnostic Laboratories, Pharma & Biotech Companies and Research & Academic Institutes for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 78: Rest of Europe Recent Past, Current & Future Analysis for Gene Panel by Application - Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Rest of Europe 6-Year Perspective for Gene Panel by Application - Percentage Breakdown of Value Sales for Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics and Other Applications for the Years 2025 & 2030
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Gene Panel by Product & Service - Test Kits and Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Rest of Europe 6-Year Perspective for Gene Panel by Product & Service - Percentage Breakdown of Value Sales for Test Kits and Testing Services for the Years 2025 & 2030
    • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for Gene Panel by End-Use - Hospital & Diagnostic Laboratories, Pharma & Biotech Companies and Research & Academic Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Rest of Europe 6-Year Perspective for Gene Panel by End-Use - Percentage Breakdown of Value Sales for Hospital & Diagnostic Laboratories, Pharma & Biotech Companies and Research & Academic Institutes for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Gene Panel Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 84: Asia-Pacific Recent Past, Current & Future Analysis for Gene Panel by Application - Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Asia-Pacific 6-Year Perspective for Gene Panel by Application - Percentage Breakdown of Value Sales for Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics and Other Applications for the Years 2025 & 2030
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Gene Panel by Product & Service - Test Kits and Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific 6-Year Perspective for Gene Panel by Product & Service - Percentage Breakdown of Value Sales for Test Kits and Testing Services for the Years 2025 & 2030
    • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for Gene Panel by End-Use - Hospital & Diagnostic Laboratories, Pharma & Biotech Companies and Research & Academic Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Asia-Pacific 6-Year Perspective for Gene Panel by End-Use - Percentage Breakdown of Value Sales for Hospital & Diagnostic Laboratories, Pharma & Biotech Companies and Research & Academic Institutes for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 90: Rest of World Recent Past, Current & Future Analysis for Gene Panel by Application - Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Rest of World 6-Year Perspective for Gene Panel by Application - Percentage Breakdown of Value Sales for Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics and Other Applications for the Years 2025 & 2030
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Gene Panel by Product & Service - Test Kits and Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of World 6-Year Perspective for Gene Panel by Product & Service - Percentage Breakdown of Value Sales for Test Kits and Testing Services for the Years 2025 & 2030
    • TABLE 94: Rest of World Recent Past, Current & Future Analysis for Gene Panel by End-Use - Hospital & Diagnostic Laboratories, Pharma & Biotech Companies and Research & Academic Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Rest of World 6-Year Perspective for Gene Panel by End-Use - Percentage Breakdown of Value Sales for Hospital & Diagnostic Laboratories, Pharma & Biotech Companies and Research & Academic Institutes for the Years 2025 & 2030

IV. COMPETITION